Nick Diamond advises clients on a complex and evolving health policy and regulatory environment.

He has particular expertise in legislative and regulatory developments impacting health insurance and quality and payment reform.

Prior to joining Avalere, Nick led global market strategy in the healthcare and life sciences sectors at MarkLogic, a technology company based in Silicon Valley. Prior to MarkLogic, he held consulting roles at MITRE and Booz Allen Hamilton, where he advised the Centers for Medicare & Medicaid Services during implementation of the ACA.

Nick is also a member of the adjunct faculty at The George Washington University and an adjunct fellow at the Center for Public Health Initiatives at the University of Pennsylvania. He holds a JD from Charleston Law, a Master of Laws in global health law from Georgetown Law, an MA in bioethics from the University of Pennsylvania, and an undergraduate degree from Georgetown.

Authored Content


The USMCA’s intellectual property provisions add additional layers of ambiguity to the already complex issues surrounding biological product exclusivity and its future in US law.

Since the 1980s, all 50 states have used immunization requirements as a condition of school entry to protect the public’s health from vaccine-preventable diseases.

State healthcare legislation often holds important implications for high-value and high-cost drugs, such as those used to treat cancer patients.

Avalere’s state policy team recently attended the National Academy for State Health Policy’s (NASHP) Annual Conference for 3 days of interactive state health policy discussions and the facilitation of a roundtable on the direction of telehealth in the states.

States are increasingly seeking to improve access and health outcomes for their underserved, rural, or homebound populations, and many are turning to telehealth as a solution.

While the majority of state legislative sessions have adjourned for 2019, at least 11 states (CT, FL, LA, IN, MD, ME, NH, NM, NV, VT, and WA) have enacted laws to create or study coverage protections against pre-existing condition exclusions and coverage of all essential health benefits (EHB) provided for in the Affordable Care Act (ACA).

While the Department of Health & Human Services (HHS) did not intend for proposed changes to Anti-Kickback Statute (AKS) regulations to impact commercial market drug negotiations, some state laws may indirectly lead to commercial market implications.

With the number of measles cases rising across the country, FDA Commissioner Scott Gottlieb raised the prospect of federal intervention over exemptions to state-level immunization school-entry requirements. While not specifying what role the federal government would play, Gottlieb stated, “You could mandate certain rules about what is and isn’t permissible when it comes to allowing people to have exemptions.”

New research shows higher cost sharing for vaccines under Part D leads to fewer seniors getting vaccines. Immunization rates are higher for vaccines covered by Part D plans with lower cost sharing.